On April 2, 2026, President Trump issued a Proclamation imposing tariffs of up to 100 percent under Section 232 of the Trade Expansion Act of 1962 on certain patented pharmaceuticals and associated pharmaceutical ingredients.
Rather than imposing a uniform tariff, the Proclamation establishes a differentiated framework that relies upon product type, country of origin, and, in some instances, company-specific commitments relating to U.S. production and pricing.
As a result, impacted stakeholders must pay close attention not only to tariff classification and product origin, but also to upcoming implementation guidance from the Department of Commerce and how this policy interacts with ongoing trade and health policy developments.